Freeline Therapeutics Shares Rise on Takeover by Syncona

Dow Jones2023-11-22

By Colin Kellaher

Freeline Therapeutics Holdings's American depositary shares rose more than 11% on Wednesday after the company agreed to be taken private by majority shareholder Syncona.

Freeline ADSs were recently changing hands at $6.40. The shares are down about 10% for the year.

The clinical-stage biotechnology company said Syncona, which already owns about 58% of Freeline, will pay $6.50 each for the remaining ADSs, a 12% premium to Tuesday's closing price and more than 50% above its closing price on Oct. 17, before Syncona revealed that is had made an initial offer of $5 per ADS.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 22, 2023 10:19 ET (15:19 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2385663525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-22 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2385663525","market":"us","top_or_hot":-1,"title":"Freeline Therapeutics Shares Rise on Takeover by Syncona","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Freeline Therapeutics Holdings's American depositary shares rose more than 11% on Wednesday after the company agreed to be taken private by majority shareholder Syncona. \n</p>\n<p>\n  Freeline ADSs were recently changing hands at $6.40.  The shares are down about 10% for the year. \n</p>\n<p>\n  The clinical-stage biotechnology company said Syncona, which already owns about 58% of Freeline, will pay $6.50 each for the remaining ADSs, a 12% premium to Tuesday's closing price and more than 50% above its closing price on Oct. 17, before Syncona revealed that is had made an initial offer of $5 per ADS. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 22, 2023 10:19 ET (15:19 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Freeline Therapeutics Shares Rise on Takeover by Syncona</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFreeline Therapeutics Shares Rise on Takeover by Syncona\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-22 23:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  Freeline Therapeutics Holdings's American depositary shares rose more than 11% on Wednesday after the company agreed to be taken private by majority shareholder Syncona. \n\n\n...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2385663525","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2385663525","pubTimestamp":1700666340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Freeline Therapeutics Holdings's American depositary shares rose more than 11% on Wednesday after the company agreed to be taken private by majority shareholder Syncona.Freeline ADSs were recently changing hands at $6.40.  The shares are down about 10% for the year.The clinical-stage biotechnology company said Syncona, which already owns about 58% of Freeline, will pay $6.50 each for the remaining ADSs, a 12% premium to Tuesday's closing price and more than 50% above its closing price on Oct. 17, before Syncona revealed that is had made an initial offer of $5 per ADS.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FRLN":"Freeline Therapeutics Holdings plc"},"translate_title":"Syncona收购Freeline Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FRLN":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Freeline Therapeutics Holdings's American depositary shares rose more than 11% on Wednesday after the company agreed to be taken private by majority shareholder Syncona. \n\n\n  Freeline ADSs were recently changing hands at $6.40.  The shares are down about 10% for the year. \n\n\n  The clinical-stage biotechnology company said Syncona, which already owns about 58% of Freeline, will pay $6.50 each for the remaining ADSs, a 12% premium to Tuesday's closing price and more than 50% above its closing price on Oct. 17, before Syncona revealed that is had made an initial offer of $5 per ADS. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 22, 2023 10:19 ET (15:19 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2385663525"}